Recursion Pharmaceuticals Inc is trading at $3.92 (+13.11%) on unusually strong early-session buying, rebounding after a period of recent weakness.
- The move appears to be a technical recovery as no fresh company-specific headlines, earnings, or FDA decisions have been reported for June 4, 2026.
- Shares are gaining ground in early-session action despite the absence of new fundamental catalysts or major analyst commentary.